Eli Mordechai, Ph.D.
Chief Executive Officer & Founder
Dr. Mordechai is the founder of this laboratory. He is a graduate of Temple University where he was the recipient of The Florence Gloria Freedman Cancer Research Award. He completed his post-graduate work at Barrow Neurological Institute specializing in molecular neurobiology. Dr. Mordechai has published many research papers in the fields of infectious disease and chronic illnesses. He is an Associate member of the American Association of Bioanalysts as well as the American Association for the Advancement of Science.
Martin E. Adelson, Ph.D.
Chief Operating Officer
Dr. Martin Adelson is a graduate of the Fels Institute for Cancer Research and Molecular Biology at Temple University and a recipient of the prestigious Daniel Swern Memorial Fellowship. While in graduate school, Dr. Adelson’s research was focused on the modulation of a natural antiviral enzyme, PKR, to provide cells with the ability to resist infection with the human immunodeficiency virus (HIV-1). Later, he went on to complete his postdoctoral studies at the University of Medicine and Dentistry of New Jersey in the field of HIV-1-based gene therapy and became the recipient of a competitive Postdoctoral Research Fellowship from the National Institutes of Health, National Lung, and Blood Institute entitled, “Pseudotyped Lentiviral Vector Gene Therapy of Hemophilia.”
In 2002, Dr. Adelson began his appointment at Medical Diagnostic Laboratories, LLC (MDL) as the Director of Research and Development and quickly became known for his expertise in the development of diagnostic assays. In the following years, Dr. Adelson led the investigation of co-infection agents aspects of Lyme disease, partnered with physicians and researchers throughout the United States on studies around clinical pathogen prevalence, and oversaw development of new clinical diagnostic assays. Dr. Adelson is also known for his innovative work in areas of laboratory automation. In 2010, as the Principal Investigator, he became a recipient of a Small Business Innovative Research (SBIR) funding grant for the development of the acoustic dispensation of nanodrops of reagents to achieve a very high-throughput of PCR-based diagnostics. Dr. Adelson has implemented various innovations and re-engineering initiatives, as well as leveraged customized technology solutions, to re-calibrate and enhance MDL’s work flow. In multiple iterations, he directly formulated the work flow and authored all of the underlying software. Each modification has resulted in a qualitatively new level of testing quality and diagnostic test throughput while reducing overall business costs.
Dr. Adelson is the author of more than 45 publications and 65 abstracts, a member of the American Society of Microbiology, the International Organization for Mycoplasmology, and the Association for Molecular Pathology. He served as a reviewer on the peer-reviewed Journal of Clinical Microbiology and Diagnostic Microbiology and The Journal of Infectious Diseases. He is also a member of the Thomas Jefferson University Biotechnology Advisory Committee, an Associate Professor at Rowan University, a Medical Director for the Wadsworth Center New York State Department of Health, on the Scientific Advisory Board of JBS Science Inc. at the PA Biotechnology Center, and a founding member of the New Jersey and Pennsylvania BioTech and Life Sciences Leadership Council. Now as the Chief Operating Officer of the Genesis Biotechnology Group, Dr. Adelson leads clinical, development, and discovery research operations in MDL, Venenum Biodesign, LLC, and Invivotek, LLC, with his main focus being shifted to scaling and expanding the existing business infrastructure through both organic growth and corporate acquisition.
Richard C. Tilton, Ph.D.
Dr. Richard C. Tilton, Board Certified in Public Health and Medical Microbiology by the American Board of Medical Microbiology, has over 30 years of experience in Clinical Microbiology and Immunology. He retired as Professor of Laboratory Medicine at the University of Connecticut School of Medicine, as well as from John Dempsey Hospital, University of Connecticut Health Center, and from the Department of Pathology in Hamilton, Bermuda. He is the founder and Medical Director of BBI Clinical Laboratories, a national reference laboratory for Infectious Diseases as well as being Founder and Principal of The Tilton Technical Group, a consulting consortium for clinical and environmental microbiology, laboratory compliance and regulation, and laboratory information systems. Dr. Tilton has published 200 peer reviewed papers and 15 books and was Editor-In-Chief of the Journal of Clinical Microbiology for a decade.